Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Study Details
Study Description
Brief Summary
This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
PRIMARY OBJECTIVES:
- To determine the optimal dose and timing of panitumumab IRDye800 infusion for identifying lung cancer compared to surrounding normal tissue in the ex vivo setting as measured by tumor to background ratio.
SECONDARY OBJECTIVES:
-
Determine the safety and tolerability of the panitumumab IRDye800 as an imaging agent in subjects undergoing resection of lung cancer.
-
Determine whether the primary lung tumor or positive lymph nodes can be detected by near-infrared (NIR) fluorescence imaging with panitumumab IRDye800 but not by white light imaging.
OUTLINE: This is a phase I, dose-escalation study of panitumumab-IRDye800 followed by a phase II study.
Participants receive panitumumab- IRDye800 intravenously (IV) over 60 minutes on day 0, and then undergo NIR and surgery within 1-5 days.
After completion of study treatment, participants are followed up for up to 30 days.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Diagnostic (panitumumab-IRDye800, surgery, NIR) Participants receive panitumumab- IRDye800 IV over 60 minutes on day 0, and then undergo NIR and surgery within 1-5 days. |
Procedure: Near-Infrared Fluorescence Imaging
Undergo imaging
Other Names:
Drug: Panitumumab-IRDye800
Given IV
Other Names:
Other: Pharmacokinetic Study
Correlative studies
Other Names:
Procedure: Therapeutic Conventional Surgery
Undergo surgery
|
Outcome Measures
Primary Outcome Measures
- Tumor to background ratio (TBR), measured in ex vivo tissues [Up to 1 year]
The TBR is defined as the near-infrared fluorescence signal of tumor or lymph node tissue compared to normal adjacent tissue measured in ex vivo tissues. Outcomes will be reported as the TBR (mean) and standard deviation for each dose group and timing group (1-2 days or 3-5 days prior to surgery).
Secondary Outcome Measures
- Number of Grade 2 or higher AEs determined to be clinically significant and definitely, probably or possibly related to study drug [Up to 30 days]
- Metastatic lesion detection by Panitumumab-IRDye800 versus standard assessments [Up to 1 year]
Intraoperative near-infrared fluorescence imaging with panitumumab-IRDye800 will be compared to conventional white light visualization and ex vivo histopathology methods to identify metastatic lesions. Outcomes will be reported as the number of metastatic lesions detected by both near-infrared fluorescence imaging and histopathology, and each method alone.
- Tumor-positive lymph node detection by Panitumumab-IRDye800 versus standard assessments [Up to 1 year]
Intraoperative near-infrared fluorescence imaging with panitumumab-IRDye800 will be compared to conventional white light visualization and ex vivo histopathology methods to identify tumor-positive lymph nodes. Outcomes will be reported as the number of tumor-positive lymph nodes detected by both near-infrared fluorescence imaging and histopathology, and each method alone.
- Residual disease detection by Panitumumab-IRDye800 versus standard assessments [Up to 1 year]
Intraoperative near-infrared fluorescence imaging with panitumumab-IRDye800 will be compared to conventional white light visualization and ex vivo histopathology methods to identify residual disease at resection margins. Outcomes will be reported as the number of positive-margins detected by both near-infrared fluorescence imaging and histopathology, and each method alone.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with lung nodule or mass concerning for malignancy, either primary lung cancer or lung metastases, whether or not it is biopsy-proven
-
Patients scheduled to undergo planned standard of care surgical resection for a lung nodule or mass with diagnostic and/or curative intent for lung cancer
-
Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level 0-2
-
Hemoglobin ≥ 9 gm/dL
-
White blood cell count > 3000/mm^3
-
Platelet count ≥ 100,000/mm^3
-
Serum creatinine ≤ 1.5 times upper reference range
Exclusion Criteria:
-
Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
-
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment
-
History of infusion reactions to monoclonal antibody therapies
-
Pregnant or breastfeeding
-
Magnesium or potassium lower than the normal institutional values
-
Subjects receiving class IA (quinidine, procanamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
-
Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
-
Prisoners, institutionalized individuals, and patients unable to consent for themselves
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Stanford University, School of Medicine | Palo Alto | California | United States | 94304 |
Sponsors and Collaborators
- Eben Rosenthal
Investigators
- Principal Investigator: Natalie Lui, Stanford University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRB-41302
- NCI-2018-00494
- LUN0099